The enzyme dipeptidyl peptidase-4 (DPP-4 ... the strategy to inhibit the enzyme has been explored. Several DPP-4 inhibitors are in clinical development; these are orally active and increase ...

This study was performed to provide an assessment of the efficacy and tolerability of sitagliptin at doses of 100 and 200 mg once daily as monotherapy in patients with type 2 diabetes with ...

The use of SGLT2 inhibitors vs DDP-4 inhibitors is associated with a reduced risk of developing different types of dementia.

SGLT-2 inhibitors were associated with the lowest risk for incidental dementia relative to DPP-4 inhibitors and GLP-1RAs in type 2 diabetes.

SGLT-2 inhibitor use vs DPP-4 inhibitor use was associated with a lower risk for incidental Parkinson disease among older adults with type 2 diabetes.

In a recent study published in BMJ, researchers from the Seoul National University, South Korea, observed type 2 diabetes patients between the ages of 40 and 69 years being treated with dipeptidyl ...

Compared with the use of dipeptidyl peptidase-4 inhibitors, the use of sodium-glucose cotransporter-2 inhibitors was associated with a 35% reduced risk for dementia in older adults with type 2 ...

Semaglutide use was associated with a lower risk for opioid overdose than other antidiabetic medications in comorbid type 2 diabetes and OUD.

A retrospective cohort study compared the rate of progression from metabolic dysfunction-associated steatotic liver disease (MASDL) to cirrhosis in people with diabetes and MASDL who were taking GLP-1 ...